Stryker Corporation SYK SPX
Healthcare · Medical Devices · United States
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
READ MORE ›$305.09
-19.50% 1Y
Market & Price
Market Cap
$116.96B
Current Price
$305.09
High / Low (52W)
$400.53 / $282.58
Beta
0.81
Valuation
Stock P/E
35.35
Industry PE
23.65
Forward P/E
18.25
PEG Ratio
1.45
Book Value
$58.61
Price to Book
5.21
P/S
4.63
EV/EBITDA
18.68
Dividend Yield
1.15%
Profitability & Returns
ROCE
12.79%
ROE
15.20%
ROA
7.72%
Profit Margin
13.21%
Op Margin
17.82%
EPS (Latest Qtr)
$1.93
EPS (TTM)
$8.63
Balance Sheet & Liquidity
Debt/Equity
0.66
Quick Ratio
1.03
Current Ratio
2.11
Debt
$15.23B
Total Assets
$47.84B
Current Assets
$14.76B
Working Capital
$6.96B
Ownership
Promoter Holding
5.37%
Chg in Prom Hold
-
FII / Inst Holding
82.31%
Chg in FII Hold
-0.01%
Financial Snapshot
Enterprise Value
$129.23B
Total Revenue (TTM)
$25.27B
EBITDA
$6.92B
Free Cash Flow
$4.36B
Operating Cash Flow
$5.38B
Shares Outstanding
383.36M
Gross Margin
64.70%
Payout Ratio
39.81%
Growth (CAGR)
Revenue 5Y
10.83%
Profit 5Y
11.24%
Revenue (YoY)
2.60%
Earnings (YoY)
14.20%
PROS
- Compounding revenue at 10.8% over 5 years.
- Profit CAGR of 11.2% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SYK Stryker Corporation SPX | 305.09 | 35.35 | $116.96B | 1.15% | 12.79% | 15.20% | 10.83% | 11.24% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 2.96B | 3.01B | 3.01B | 3.47B | 3.24B | 3.32B | 3.24B | 3.80B | 3.52B | 3.65B | 3.59B | 4.13B | 3.59B | 2.76B | 3.74B | 4.26B | 3.95B | 4.29B | 4.16B | 4.70B | 4.28B | 4.49B | 4.48B | 5.20B | 4.78B | 5.00B | 4.91B | 5.82B | 5.24B | 5.42B | 5.49B | 6.44B | 5.87B | 6.02B | 6.06B | 7.17B | 6.02B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.12B | 2.18B | 2.21B | 2.54B | 2.21B |
| Gross Profit | 1.84B | 1.87B | 2.09B | 1.96B | 1.99B | 1.98B | 2.24B | 2.14B | 2.19B | 2.15B | 2.46B | 2.28B | 2.38B | 2.33B | 2.70B | 2.33B | 1.55B | 2.46B | 2.72B | 2.51B | 2.77B | 2.64B | 3.04B | 2.73B | 2.83B | 2.78B | 3.24B | 3.02B | 3.18B | 3.16B | 3.70B | 3.33B | 3.42B | 3.52B | 4.17B | 3.74B | 3.84B | 3.85B | 4.63B | 3.81B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.87B | 2.67B | 2.64B | 2.82B | 2.87B |
| Operating Income | 500.00M | 486.00M | - | 556.00M | 502.00M | 525.00M | - | 591.00M | 672.00M | 576.00M | - | 528.00M | 613.00M | 628.00M | - | 635.00M | -20.00M | 859.00M | - | 459.00M | 732.00M | 574.00M | - | 447.00M | 772.00M | 808.00M | - | 735.00M | 965.00M | 931.00M | - | 972.00M | 1.05B | 1.08B | - | 872.00M | 1.17B | 1.21B | 1.81B | 936.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17B | 1.46B | 1.52B | 2.19B | 1.30B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.00M | - | - | - | 148.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 764.00M | 1.02B | 1.03B | 1.71B | 850.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 110.00M | 132.00M | 170.00M | 856.00M | 105.00M |
| Net Income | 380.00M | 355.00M | 510.00M | 444.00M | 391.00M | 434.00M | -249.00M | 443.00M | 452.00M | 590.00M | 2.07B | 412.00M | 480.00M | 466.00M | 725.00M | 493.00M | -83.00M | 621.00M | 568.00M | 302.00M | 592.00M | 438.00M | 662.00M | 323.00M | 656.00M | 816.00M | 563.00M | 592.00M | 738.00M | 692.00M | 1.14B | 788.00M | 825.00M | 834.00M | 546.00M | 654.00M | 884.00M | 859.00M | 849.00M | 745.00M |
| Diluted EPS | 1.00 | 0.94 | 1.34 | 1.17 | 1.03 | 1.14 | -0.66 | 1.16 | 1.19 | 1.55 | 5.44 | 1.09 | 1.26 | 1.23 | 1.90 | 1.30 | -0.22 | 1.63 | 1.49 | 0.79 | 1.55 | 1.14 | 1.73 | 0.84 | 1.72 | 2.14 | 1.47 | 1.54 | 1.93 | 1.80 | 2.98 | 2.05 | 2.14 | 2.16 | 1.41 | 1.69 | 2.29 | 2.22 | 2.20 | 1.93 |
| R&D Expense | 183.00M | 184.00M | - | 192.00M | 192.00M | 198.00M | - | 204.00M | 216.00M | 221.00M | - | 225.00M | 246.00M | 246.00M | - | 254.00M | 233.00M | 242.00M | - | 288.00M | 310.00M | 306.00M | - | 413.00M | 351.00M | 364.00M | - | 339.00M | 346.00M | 353.00M | - | 368.00M | 363.00M | 377.00M | - | 405.00M | 407.00M | 410.00M | - | 413.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 11.32B | 12.44B | 13.60B | 14.88B | 14.35B | - | 18.45B | 20.50B | 22.59B | 25.12B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.87B | 7.44B | 8.15B | 9.05B |
| Gross Profit | 4.14B | 4.59B | 4.54B | 5.03B | 5.50B | 5.88B | 6.02B | 6.36B | 6.60B | 7.50B | 8.18B | 8.94B | 9.70B | 9.06B | - | 11.58B | 13.06B | 14.44B | 16.07B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.47B | 9.13B | 9.77B | 11.01B |
| Operating Income | 1.31B | 1.52B | 1.59B | 1.75B | 1.69B | 1.74B | 1.26B | 1.25B | 1.86B | 2.17B | 2.30B | 2.54B | 2.71B | 2.22B | - | 3.11B | 3.92B | 4.67B | 5.06B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.11B | 5.06B | 4.95B | 6.31B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 363.00M | 409.00M | 607.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.68B | 3.67B | 3.49B | 4.51B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 325.00M | 508.00M | 499.00M | 1.27B |
| Net Income | 1.02B | 1.15B | 1.11B | 1.27B | 1.34B | 1.30B | 1.01B | 515.00M | 1.44B | 1.65B | 1.02B | 3.55B | 2.08B | 1.60B | - | 2.36B | 3.17B | 2.99B | 3.25B |
| Diluted EPS | 2.44 | 2.78 | 2.77 | 3.19 | 3.45 | 3.39 | 2.63 | 1.34 | 3.78 | 4.35 | 2.68 | 9.34 | 5.48 | 4.20 | - | 6.17 | 8.25 | 7.76 | 8.40 |
| R&D Expense | 375.30M | 367.80M | 336.00M | 394.00M | 462.00M | 471.00M | 536.00M | 614.00M | 625.00M | 715.00M | 787.00M | 862.00M | 971.00M | 984.00M | 1.24B | 1.45B | 1.39B | 1.47B | 1.62B |
Compounded Sales Growth
| 5 Years: | 10.83% |
| 1 Year: | 2.60% |
Compounded Profit Growth
| 5 Years: | 11.24% |
| 1 Year: | 14.20% |
Stock Price Performance
| 1 Year: | -19.50% |
| 6 Months: | -18.24% |
| 3 Months: | -21.05% |
| 1 Month: | -3.19% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 7.60B | 9.07B | 10.66B | 12.15B | 13.21B | 15.40B | 17.26B | 16.22B | 20.43B | 22.20B | 27.23B | 30.17B | 34.33B | - | 36.88B | 39.91B | 42.97B | 47.84B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.28B | 12.52B | 14.85B | 14.76B |
| Cash & Equivalents | 416.60M | 290.50M | 701.00M | 659.00M | 1.76B | 905.00M | 1.40B | 1.34B | 1.79B | 3.38B | 3.32B | 2.54B | 3.62B | 4.34B | 2.94B | - | 1.84B | 2.97B | 3.65B | 4.01B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.00B | 4.84B | 4.77B | 5.31B |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.56B | 3.77B | 3.99B | 4.04B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | 7.71B | 10.88B | 12.22B | 15.50B | 17.36B | 21.25B | - | 20.27B | 21.32B | 22.34B | 25.42B |
| Current Liabilities | - | - | 1.46B | 1.44B | 1.60B | 1.84B | 1.88B | 2.66B | 4.46B | 3.50B | 3.15B | 3.48B | 4.81B | 4.40B | 5.04B | - | 6.30B | 7.92B | 7.62B | 7.79B |
| Long Term Debt | - | - | - | - | 996.00M | 1.75B | 1.75B | 2.74B | 3.25B | 3.23B | 6.69B | 6.59B | 8.49B | 10.23B | 13.23B | - | 11.86B | 10.90B | 12.19B | 14.86B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.05B | 12.99B | 13.60B | 15.86B |
| Total Equity | 4.19B | 5.38B | 5.41B | 6.60B | 7.17B | 7.68B | 8.60B | 9.05B | 8.60B | 8.51B | 9.55B | 9.97B | 11.73B | - | - | - | 16.62B | 18.59B | 20.63B | 22.42B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 378.70M | 380.10M | 381.40M | 382.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.03B | 1.18B | 1.46B | 1.55B | 1.43B | 1.66B | 1.89B | 1.78B | 981.00M | 1.92B | 1.56B | 2.61B | 2.19B | 3.28B | - | 2.62B | 3.71B | 4.24B | 5.04B |
| Investing Cash Flow | -1.18B | 310.10M | -1.33B | -795.00M | -2.13B | -736.00M | -2.22B | -1.88B | 1.96B | -4.19B | -1.61B | -2.86B | -1.46B | -4.70B | - | -2.92B | -962.00M | -3.00B | -4.87B |
| Financing Cash Flow | 13.60M | -1.05B | -193.00M | 410.00M | -161.00M | -449.00M | 300.00M | 629.00M | -1.22B | 2.26B | -794.00M | 1.33B | 3.00M | -11.00M | - | -749.00M | -1.59B | -525.00M | 113.00M |
| Capital Expenditure | -187.70M | -155.20M | -131.00M | -182.00M | -226.00M | -210.00M | -195.00M | -233.00M | -270.00M | -490.00M | -598.00M | -572.00M | -649.00M | -487.00M | - | -588.00M | -575.00M | -755.00M | -761.00M |
| Free Cash Flow | 840.60M | 1.02B | 1.33B | 1.36B | 1.21B | 1.45B | 1.69B | 1.55B | 711.00M | 1.43B | 961.00M | 2.04B | 1.54B | 2.79B | - | 2.04B | 3.14B | 3.49B | 4.28B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.05B | 1.16B | 717.00M | 291.00M |
| Share Buybacks | 0 | 1.00B | 0 | 426.00M | 622.00M | 108.00M | 317.00M | 100.00M | 700.00M | 13.00M | 230.00M | 300.00M | 307.00M | 0 | 0 | - | - | - | - |
| Dividends Paid | 89.70M | 135.60M | 198.00M | 238.00M | 279.00M | 324.00M | 401.00M | 462.00M | 521.00M | 568.00M | 636.00M | 703.00M | 778.00M | 863.00M | 950.00M | 1.05B | 1.14B | 1.22B | 1.28B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 66.3% | 65.7% | 65.7% | 65.1% | 63.1% | - | 62.8% | 63.7% | 63.9% | 64.0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | 19.2% | 18.5% | 18.7% | 18.2% | 15.5% | - | 16.9% | 19.1% | 20.7% | 20.1% |
| Net Margin % | - | - | - | - | - | - | - | - | - | 14.5% | 8.2% | 26.1% | 14.0% | 11.1% | - | 12.8% | 15.4% | 13.2% | 12.9% |
| ROE % | 18.9% | 21.2% | 16.8% | 17.7% | 17.5% | 15.1% | 11.1% | 6.0% | 16.9% | 17.2% | 10.2% | 30.3% | - | - | - | 14.2% | 17.0% | 14.5% | 14.5% |
| ROCE % | - | 24.7% | 20.9% | 19.3% | 16.4% | 15.4% | 9.9% | 9.7% | 14.6% | 12.6% | 12.3% | 11.3% | 10.5% | 7.6% | - | 10.2% | 12.3% | 13.2% | 12.6% |
Shareholding Pattern
Insiders
5.37%
Institutions
82.31%
Public Float
86.98%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.20% | 27.60M | $8.42B |
| 2 | Vanguard Capital Management LLC | 5.84% | 22.38M | $6.83B |
| 3 | Greenleaf Trust | 4.16% | 15.94M | $4.86B |
| 4 | JPMORGAN CHASE & CO | 4.07% | 15.60M | $4.76B |
| 5 | State Street Corporation | 4.00% | 15.35M | $4.68B |
| 6 | Price (T.Rowe) Associates Inc | 2.62% | 10.04M | $3.06B |
| 7 | Vanguard Portfolio Management LLC | 2.17% | 8.33M | $2.54B |
| 8 | Wellington Management Group, LLP | 2.12% | 8.12M | $2.48B |
| 9 | Geode Capital Management, LLC | 2.02% | 7.75M | $2.36B |
| 10 | Morgan Stanley | 1.64% | 6.30M | $1.92B |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SYK
No recent headlines available.